We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · May 24, 2021

Switching to Ocrelizumab From Natalizumab for RRMS Patients at Risk of Progressive Multifocal Leukoencephalopathy

Multiple Sclerosis (Houndmills, Basingstoke, England)

 

Additional Info

Multiple Sclerosis (Houndmills, Basingstoke, England)
Switching to Ocrelizumab in RRMS Patients at Risk of PML Previously Treated With Extended Interval Dosing of Natalizumab
Mult. Scler. 2021 Apr 01;27(5)790-794, CR Mancinelli, C Scarpazza, C Cordioli, N De Rossi, S Rasia, MV Turrini, R Capra

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading